TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group - PubMed (original) (raw)
Clinical Trial
. 1999 Aug 11;53(3):457-65.
- PMID: 10449104
Clinical Trial
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group
No authors listed. Neurology. 1999.
Abstract
Objective: A double-blind, placebo-controlled phase II study was conducted in 168 patients, most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions on MRI.
Background: Tumor necrosis factor (TNF) has been implicated in MS pathogenesis, has been identified in active MS lesions, is toxic to oligodendrocytes in vitro, and worsens the severity of experimental allergic encephalomyelitis (EAE) in animals. Lenercept, a recombinant TNF receptor p55 immunoglobulin fusion protein (sTNFR-IgG p55), protects against EAE.
Methods: Patients received 10, 50, or 100 mg of lenercept or placebo IV every 4 weeks for up to 48 weeks. MRI scans and clinical evaluations were performed at screening, at baseline, and then every 4 weeks (immediately before dosing) through study week 24.
Results: There were no significant differences between groups on any MRI study measure, but the number of lenercept-treated patients experiencing exacerbations was significantly increased compared with patients receiving placebo (p = 0.007) and their exacerbations occurred earlier (p = 0.006). Neurologic deficits tended to be more severe in the lenercept treatment groups, although this did not affect Expanded Disability Status Scale scores. Anti-lenercept antibodies were present in a substantial number of treated patients; serum lenercept trough concentrations were detectable in only a third. Adverse events that increased in frequency in treated patients included headache, nausea, abdominal pain, and hot flushes.
Conclusions: Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.
Comment in
- Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss.
Schwid SR, Noseworthy JH. Schwid SR, et al. Neurology. 1999 Aug 11;53(3):444-5. doi: 10.1212/wnl.53.3.444. Neurology. 1999. PMID: 10449101 No abstract available.
Similar articles
- Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE, Weisman M, Paulus HE, Bulpitt K, Weinblatt M, Polisson R, Zaug M, Kneer J, Van der Auwera P, Stevens RM. Furst DE, et al. J Rheumatol. 2003 Oct;30(10):2123-6. J Rheumatol. 2003. PMID: 14528504 Clinical Trial. - Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, Kneer J, van der Auwera P, Stevens RM; Rheumatology Group 791. Rau R, et al. J Rheumatol. 2003 Apr;30(4):680-90. J Rheumatol. 2003. PMID: 12672184 Clinical Trial. - Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. Hurwitz BJ, et al. Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013. Clin Ther. 2008. PMID: 18640466 Clinical Trial. - Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ. Fox EJ. Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013. Clin Ther. 2006. PMID: 16750460 Review. - Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre L, Walley KR. McIntyre L, et al. Crit Care Med. 2001 Mar;29(3):677-9. doi: 10.1097/00003246-200103000-00044. Crit Care Med. 2001. PMID: 11373447 Review. No abstract available.
Cited by
- Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort.
Dos Santos A, Courtin E, Ruet A, Duffau P, Mathey G, Bekkour I, Ciron J, Michel L, Blanc FX, Aguilar J, Lejeune P, Marc G, Laplaud D, Magot A, Hamidou M, Wiertlewski S. Dos Santos A, et al. Brain Behav. 2024 Sep;14(9):e3443. doi: 10.1002/brb3.3443. Brain Behav. 2024. PMID: 39279263 Free PMC article. - Neurodegeneration and demyelination in multiple sclerosis.
Garton T, Gadani SP, Gill AJ, Calabresi PA. Garton T, et al. Neuron. 2024 Oct 9;112(19):3231-3251. doi: 10.1016/j.neuron.2024.05.025. Epub 2024 Jun 17. Neuron. 2024. PMID: 38889714 Review. - Oligodendrocytes in central nervous system diseases: the effect of cytokine regulation.
Zhang C, Qiu M, Fu H. Zhang C, et al. Neural Regen Res. 2024 Oct 1;19(10):2132-2143. doi: 10.4103/1673-5374.392854. Epub 2024 Jan 8. Neural Regen Res. 2024. PMID: 38488548 Free PMC article. - Tumor necrosis factor receptor 2 activation elicits sex-specific effects on cortical myelin proteins and functional recovery in a model of multiple sclerosis.
Nguyen KL, Bhatt IJ, Gupta S, Showkat N, Swanson KA, Fischer R, Kontermann RE, Pfizenmaier K, Bracchi-Ricard V, Bethea JR. Nguyen KL, et al. Brain Res Bull. 2024 Feb;207:110885. doi: 10.1016/j.brainresbull.2024.110885. Epub 2024 Jan 20. Brain Res Bull. 2024. PMID: 38246200 Free PMC article. - The mechanism by which cannabidiol (CBD) suppresses TNF-α secretion involves inappropriate localization of TNF-α converting enzyme (TACE).
Frodella CM, Liu L, Tan W, Pruett SB, Kaplan BLF. Frodella CM, et al. Cell Immunol. 2024 Mar-Apr;397-398:104812. doi: 10.1016/j.cellimm.2024.104812. Epub 2024 Jan 17. Cell Immunol. 2024. PMID: 38245915
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical